Kaplan-Meier survival curves for patients with increased CD86 expression on plasma cells at diagnosis (B7-2–positive myeloma) compared with normal or reduced CD86 expression at diagnosis (B7-2–negative myeloma).

The median survival for B7-2–positive myeloma was 28 months and for B7-2–negative myeloma was 57 months (χ² = 4.6;P = .03). (▴), % CD86 high; (▪), % CD86 normal.